Medical device giant Medtonic has launched InPen, the first FDA-cleared smart insulin pen for diabetes patients needing multiple daily injections.

The Dublin company’s diabetes division, based in Northridge, announced the product launch on Thursday.


InPen uses Medtronic’s Guardian Connect Continuous Glucose Monitoring data to provide a patient with real-time glucose readings and insulin dose information — resulting in a more independent take on diabetes management, the company said in a statement.


Medronic acquired San Diego-based Companion Medical, manufacturer of the InPen, in September. The decision brought together Medtronic’s CGM software and InPen’s ability to measure the right dose of insulin in one medical device, Medtronic said.


“Our successful integration of these devices in just two months following the close of our Companion Medical acquisition is a testament to the close collaboration of our employees and strong passion to serve our customers with better solutions to manage their diabetes,” Sean Salmon, president of the Diabetes Business at Medtronic, said in a statement.


Shares of Medtronic (MDT) closed Friday up $2.90, or nearly 2.7 percent, to $112.50 on the New York Stock Exchange.